Evaluating patients at risk for antinuclear antibody (ANA)-associated systemic autoimmune rheumatic diseases, particularly systemic lupus erythematosus (SLE), Sjögrens syndrome, and mixed connective tissue disease. This includes assessing patients who present with signs and symptoms of a connective tissue disease and have tested positive for antinuclear antibodies (ANA). The evaluation aims to confirm the diagnosis, determine disease progression, and guide appropriate management and treatment.